2nd Translational Research E-Conference
Chronic Lymphocytic Leukaemia
March 17-20, 2022
#ESHCLL2022
Chairs: Jennifer Brown, Paolo Ghia, Michael Hallek
BREAKING NEWS!
In view of continuing COVID-19 related challenges and uncertainties,
the 2nd Translational Research Conference ON Chronic Lymphocytic Leukaemia
will be held as a VIRTUAL EVENT.
The safety of our speakers and attendees comes first.
We successfully transformed our last 14 conferences into E-Conferences
and will place you in the best dispositions to enjoy the presentations and discussions.
Participants will be joining us from all over the world and from different time zones.
To make sure that everyone has access to the full scientific programme
at a convenient hour, registration will allow participants to join both
the LIVE PROGRAMME: March 17-20, 2022
and the PROGRAMME ON-DEMAND: March 8 – April 20, 2022
REGISTRATION IS OFFERED FREE OF CHARGE
as a gesture of solidarity during these difficult times.
REGISTRATION NOW OPEN!
About the Conference
The 2nd ESH TRANSLATIONAL RESEARCH CONFERENCE ON CHRONIC LYMPHOCYTIC LEUKAEMIA can now be held in person to achieve again scientific interactions that are the primary goal of our gathering. The Conference is proposing a programme of leading-edge basic and clinical science where a panel of global experts in the field will provide numerous opportunities for formal and informal interactions to discuss the present and the future of CLL research. It is open to an international audience of biologists and clinicians, particularly welcoming those in-training.
This translational research conference will explore the most recent advances in the understanding of the pathogenesis and clinical management of the disease. Open and spirited discussion on the most up-to-date information in the field is expected to understand how the many new biologic insights apply to the future of CLL.
SCIENTIFIC TOPICS:
• Spectrum of CLL disease: MBL to Richter’s transformation
• New insights in “old” biomarkers
• Taking driver gene mutations to the next level
• Beyond BcR: other microenvironmental stimuli
• Time-limited therapy
• Covalent BTK inhibitors
• BTK and Bcl2 inhibitor resistance
• Next generation therapies
• The future: other targets
LEARNING OBJECTIVES:
Upon completion of this CME activity, participants should be able to:
• Understand recent advances in elucidating the pathogenesis of CLL
• Describe recent data on the use of prognostic/predictive factors
• Become familiar with the decision-making process for the novel therapeutics for CLL
• Understand emerging data on mechanisms of resistance to targeted agents in CLL
• Understand the debate about how best to optimize CLL therapy in the future
THE PROGRAMME WILL INCLUDE:
• Plenary Sessions
• Panel Discussions
• Simultaneous Meet the Expert Sessions
• Mentored Poster Walks
• Brief Oral Communications
This meeting will be of interest to:
• Senior biologists and clinicians, including experts in the field (MD, PhD, MD-PhD)
• Junior biologists and clinicians (MD, PhD)
• Clinical residents still in-training
• Allied health care professionals
SUBMISSION OF ABSTRACTS IS NOW CLOSED.
Abstracts guidelines:
– Your abstract has to be structured (eg Objectives, Methods, Results, Conclusions)
– Maximum number of words: 500
– Your abstract will be submitted to the peer review procedure.
The following file types may be uploaded: HTML document (*.htm), HTML document (*.html), JPEG image (*.jpg), GIF image (*.gif), or PNG image (*.png).
N/A
Virtual tour of the E-Conference platform:
The registration for the ESH 2nd Translational Research Conference on Chronic Lymphocytic Leukaemia is offered FREE OF CHARGE, as a gesture of solidarity during these difficult times.
Meet the Expert sessions: Registration fee: 20€
These sessions will be open to E-Conference academic biologists and clinicians registrants only. A maximum of 30 seats will be available in each session and pre-registration will therefore be required.